EFFECT OF ACUTE AND PROLONGED GLIMEPIRIDE THERAPY ON INSULIN SECRETION

本研究的目的是确定S的作用机制。 一种正在研究的新药格列美脲，一种磺脲类药物，改善了 NIDDM患者的血糖控制与吸收后的特殊参照 葡萄糖动态平衡。格列美脲被认为是通过改善这两种情况而起作用的 胰岛素分泌和胰岛素敏感性。糖尿病患者和正常人 会有一夜的肝脏葡萄糖产生，高血糖钳夹和 在四个月前和四个月后进行的正常血糖钳夹研究 格列美脲。

The objective of this study is to determine the mechanism (s) by which an investigational new drug glimepiride, a sulfonylurea, improves glycemic control in NIDDM with specific reference to post absorptive glucose homeostasis. Glimepiride is thought to act by improving both insulin secretion and insulin sensitivity. Diabetic and normal subjects will have overnight hepatic glucose production, hyperglycemic clamp and euglycemic clamp studies done before and after four months of glimepiride.